系统分析.pdf

Gonadotropin-releasing hormone analog cotreatment
for preservation of ovarian function during gonadotoxic
chemotherapy: a systematic review and meta-analysis
Mohamed A. Bedaiwy, ., .,a,b Ahmed M. Abou-Setta, ., .,c Nina Desai, ., .,d
William Hurd, .,a David Starks, .,a Sherif A. El-Nashar, ., .,b
Hesham G. Al-Inany, ., .,e and Tommaso Falcone,
a Department of Obstetrics and Gynecology, University Hospitals Case Medical Center, Case Western Reserve University,
Cleveland, Ohio; b Department of Obstetrics and Gynecology, Assiut University Hospitals, Assiut, Egypt; c Alberta Research
Centre for Health Evidence (ARCHE), University of Alberta, Edmonton, Alberta, Canada; d Department of Obstetrics and
Gynecology, and Women’s Health institute, Cleveland Clinic Foundation, Cleveland, Ohio; and e Department of Obstetrics
and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt
Objective: To determine whether gonadotropin-releasing hormone (GnRH) analog cotreatment with chemotherapy
provides better reproductive outcomes for women at risk of premature ovarian failure (POF) as a side-effect of
gonadotoxic chemotherapy.
Design: Systematic review and meta-analysis.
Setting: University-affiliated research centers.
Patient(s): None.
Intervention(s): Electronic and manual searches (., MEDLINE, EMBASE, CENTRAL) up to January 2010
were performed to identify randomized controlled trials (RCTs) comparing GnRH cotreatment with chemotherapy
alone in premenopausal women.
Main Outcome Measure(s): Incidence of POF after treatment, incidence of women with resumption of ovulation,
POF after an initial normal cycle, normal cycles but abnormal markers of ovarian reserv